While multimorbidity was common in this T2D cohort, it was not associ (Diabetes Research and Clinical Practice)ated with HbA1c, CV or TIR. Future studies should explore factors other than glycaemia that contribute to the increased mortality observed in those with multimorbidity and T2D
Diabetes News
Tag: Type 2 Diabetes
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)
Type 2 diabetes and metabolic surgery guidelines and recommendations should urgently be unified
A more harmonious discussion and unified guidelines between clinicians and surgeons are needed in order to provide the same message for those who read different articles (Acta Diabetologica)
Triglyceride-glucose index predicts independently type 2 diabetes mellitus risk: A systematic review and meta-analysis of cohort studies
TyG index has a positive and significant association with T2D risk, suggesting that the TyG index may become an applicable tool to identify subjects with T2D risk (Primary Care Diabetes)
Lower Cardiorenal Risk with Sodium‐Glucose Cotransporter‐2 Inhibitors versus Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases
In this multinational observational study, SGLT2i was associated with lower risk of heart failure and chronic kidney disease versus DPP4i in T2D patients otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes
Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin (Diabetologia)
Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes
Synopsis of the 2020 American Diabetes Association’s Standards of Medical Care in Diabetes Clinical Guideline (Annals of Internal Medicine)
Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis
These data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is (Primary Care Diabetes)
Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis
The clinical effectiveness of liraglutide is maintained long term (up to 5 years). Liraglutide treatment is not associated with higher total direct healthcare costs (Diabetes Therapy)
Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis
The addition of DPP4i to insulin is associated with a statistically significant reduction in glycemic control as measured by HbA1c, fasting plasma glucose, and 2-h postprandial glucose, without increasing the risk of hypoglycemia and weight gain. These conclusions were also observed in both stable-dose and flexible-dose insulin subgroups (Diabetes Therapy)
SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
SGLT2 inhibitors may confer a specific AF/AFL-reduction benefit in the susceptible type 2 diabetes population, regardless of age, body weight, HbA1c, and systolic blood pressure at baseline (Cardiovascular Diabetology)
Dietary strategies to manage diabetes and glycemic control in youth and young adults with youth‐onset type 1 and type 2 diabetes
For several dietary strategies, more frequent use over time was related to lower A1c in youth‐onset type 1 and type 2 diabetes, suggesting these strategies can likely support diabetes management for this population (Pediatric Diabetes)
Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis
This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy (Journal of Clinical Endocrinology & Metabolism)
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
In clinical trials, oral semaglutide 14 mg reduced mean HbA1c by approximately 1.1–1.5% and reduced body weight by up to 5 kg. The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may offer a practical and effective means of managing people living with T2D who require treatment intensification, and may change the paradigm of care in the primary care setting (Primary Care Diabetes)
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study (Diabetes Care)
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability (Diabetes Therapy)
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial
Glycated haemogobin exhibits a U‐shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7% (International Journal of Heart Failure)
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study
Deaths in people with type 1 and type 2 diabetes rose sharply during the initial COVID-19 pandemic in England. Increased COVID-19-related mortality was associated not only with cardiovascular and renal complications of diabetes but, independently, also with glycaemic control and BMI (The Lancet Diabetes & Endocrinology)
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study
The results of this nationwide analysis in England show that type 1 and type 2 diabetes were both independently associated with a significant increased odds of in-hospital death with COVID-19 (The Lancet Diabetes & Endocrinology)
- 1
- 2
- 3
- …
- 47
- Next Page »
Glycosmedia is also available as an App: